Results 121 to 130 of about 67,683 (260)

Neurofibromatosis Type 1: Optimizing Management with a Multidisciplinary Approach

Journal of Multidisciplinary Healthcare
Shaan Lalvani, Rebecca M Brown Department of Neurology, The Mount Sinai Hospital, New York, NY, USACorrespondence: Rebecca M Brown, MD, PhD, The Mount Sinai Hospital, Department of Neurology, 1216 5th Avenue, New York, NY, 10029, USA, Tel +1 2128248579 ...
Lalvani S, Brown RM
doaj  

The NF1 tumor suppressor regulates PD-L1 and immune evasion in melanoma

Cell Reports
Summary: Hotspot BRAF, hotspot NRAS, and NF1 loss-of-function mutations are found in approximately 50%, 25%, and 15% of cutaneous melanomas, respectively. Compared to mutant BRAF and NRAS, the role of NF1 loss in melanoma remains understudied.
Diana Berry, Dan Moldoveanu, Shivshankari Rajkumar, Mathieu Lajoie, Tiffany Lin, Daméhan Tchelougou, Samridhi Sakthivel, Itai Sharon, Antoine Bernard, Sandy Pelletier, Yael Ripstein, Alan Spatz, Wilson H. Miller, Rahima Jamal, Réjean Lapointe, Anne-Marie Mes-Masson, Kevin Petrecca, Ari-Nareg Meguerditchian, Keith Richardson, Beatrice Wang, May Chergui, Marie-Christine Guiot, Kevin Watters, John Stagg, T. Martin Schmeing, Francis Rodier, Simon Turcotte, Catalin Mihalcioiu, Sarkis Meterissian, Ian R. Watson   +29 more
doaj   +1 more source

Benefit of immune checkpoint inhibitors as adjuvant treatment for acral melanomas

Journal of the European Academy of Dermatology and Venereology, EarlyView.
When questioning the effectiveness of adjuvant immunotherapy for acral melanomas, we found no clinical benefit to the adjuvant proposal, despite the maintenance of adverse effects. Abstract Background Solar factors play no role in the development of acral melanoma (AM). AM is characterized by low cumulative solar damage (low CSD).
Damien Sanogo, Romain Levard, Julie Cassecuel, Amir Khammari, Gaelle Quereux, Florent Grange, Henri Montaudié, Florence Brunet‐Possenti, Justine Lavaud, Marie‐Thérèse Leccia, Géraldine Jeudy, Anne Dompmartin, Brigitte Dreno, Jean‐Matthieu L’Orphelin   +13 more
wiley   +1 more source

International Dermoscopy Society consensus recommendations for the management of lentigo maligna

Journal of the European Academy of Dermatology and Venereology, EarlyView.
Lentigo maligna (LM) poses diagnostic and therapeutic challenges amid rising incidence and limited high‐quality evidence. This international expert consensus provides pragmatic, evidence‐based and expertise‐informed guidance on LM diagnosis and management.
Ana‐Maria Forsea, Riccardo Pampena, Bengu Nisa Akay, Zoe Apalla, Giuseppe Argenziano, Giulia Briatico, Ralph Braun, Horacio Cabo, Raul Cabrera, Cristina Carrera, Elisa Cinotti, Claudio Conforti, Enzo Errichetti, Gerardo Ferrara, Roberta Giuffrida, Stefania Guida, Pascale Guitera, Allan C. Halpern, Stephen Heyes, Rainer Hofmann‐Wellenhof, Angela M. Hong, Natalia Jaimes, Raimonds Karls, Harald Kittler, Teresa Kränke, Konstantinos Liopyris, Jie Liu, Caterina Longo, Josep Malvehy, Ashfaq A. Marghoob, Hoda Moneib, David Moreno Ramirez, Elvira Moscarella, Eduardo Nagore, Cristian Navarrete‐Dechent, John Paoli, Giovanni Pellacani, Ketty Peris, Susana Puig, Cliff Rosendahl, Lidia Rudnicka, Ahmed Sadek, Philippe Saiag, Gabriel Salerni, Alon Scope, Hans Peter Soyer, Michela V. Starace, Wilhelm Stolz, David L. Swanson, Luc Thomas, Philipp Tschandl, Iris Zalaudek, Aimilios Lallas   +52 more
wiley   +1 more source

Periodontal Disease and Salivary Gland Dysfunction in Neurofibromatosis Type 1: A Case–Control Study

Oral Diseases, EarlyView.
ABSTRACT Objectives Neurofibromatosis type 1 (NF1) presents with diverse systemic and oral manifestations. The aim of this study was to investigate the periodontal status and salivary alterations in NF1 individuals. Methods A total of 38 individuals with NF1 diagnostic criteria were compared with a control group paired by age and sex.
Eloá Borges Luna, Gustavo de Souza Vieira, Flávia Lima Kleinsorgen Motta, Ana Beatriz Oliveira Gambôa, Analúcia Rampazzo Xavier, Rafaela Elvira Rozza‐de‐Menezes, Karin Soares Cunha   +6 more
wiley   +1 more source

A Case of Pediatric Spitz Melanoma With a ZEB2::ALK Fusion

Pediatric Dermatology, EarlyView.
ABSTRACT We present a rare case of Spitz melanoma in a 3‐year‐old male patient with a ZEB2::ALK fusion. This ALK‐fused tumor exhibited aggressive behavior, recurring after an initial wide local excision and progressing despite neoadjuvant immunotherapy with a PD‐1 inhibitor.
Nathanael C. Jensen, Shadai Gociman, Sarah D. Cipriano, Casey Mehrhoff   +3 more
wiley   +1 more source

Transfusion‐related alpha‐gal syndrome: Two new cases expanding the demographic and geographic spectrum, and evidence of a diagnostic gap in allergic transfusion reaction evaluation

Transfusion, EarlyView.
Abstract Background Transfusion‐related alpha‐gal syndrome (TRAGS) has recently been proposed as a cause of allergic transfusion reactions (ATRs) in which alpha‐gal‐specific IgE in sensitized group O (or potentially group A) recipients reacts with epitopes on group B or AB plasma‐containing components.
Mackenzie Foster, Miriam Brown, Angela Mueller, Toufik Tahiri, Kaycie Atchison, Deva Sharma, Cosby A. Stone Jr., Jonathan Tucci, Garrett S. Booth, Jeremy W. Jacobs   +9 more
wiley   +1 more source

Quality of Life in Children with Neurofibromatosis Type 1: Agreement between Parents and Patients, and the Role of Disease Severity and Visibility

Children
Background: Neurofibromatosis type 1 (NF1) is a genetic disorder that affects multiple systems in the body, often leading to physical disfigurements and a wide range of clinical symptoms.
Nicola Davide Cavallo, Paola Maietta, Silverio Perrotta, Pasquale Moretta, Marco Carotenuto, Maria Esposito, Gabriella Santangelo, Claudia Santoro   +7 more
doaj   +1 more source

Rapid Response to Trametinib Combined With Chemotherapy for Infant BRAF‐Fused Chiasmatic Glioma

Pediatric Blood &Cancer, Volume 73, Issue 6, June 2026.
ABSTRACT Infants, less than 1 year, with chiasmatic gliomas (ICG) present a major therapeutic challenge due to large tumor size, decreased vision, rapid progression, and poor response to vincristine/carboplatin chemotherapy. The majority have a BRAF fusion, which may respond to downstream MEK inhibitors but response time is slow. There are no safety or
Helen Toledano, Alexander Yelak, Walid Kaadan, Shlomo Caduri, Rivka Friedland, Orli Michaeli, Gad Dotan, Osnat Konen   +7 more
wiley   +1 more source

Clinical, Genetic, and Pathologic Variability in Myelodysplastic Syndromes and Precursor Conditions Across Race, Ethnicity, and Sex

American Journal of Hematology, Volume 101, Issue 6, Page 1407-1420, June 2026.
ABSTRACT The epidemiology of myelodysplastic syndromes/neoplasms (MDS) is challenging to define due to inconsistent reporting, complex diagnostic procedures, and evolving diagnostic criteria. Using the National MDS Natural History Study—a prospective cohort with centrally adjudicated histopathology and genetic variant review—we characterized the ...
Nancy Gillis, Christelle Colin‐Leitzinger, Yi‐Han Tang, Michael Otterstatter, Seth Sherman, Ling Zhang, Lynn C. Moscinski, Mary Ellen Walker, Jeffrey S. Painter, Gregory A. Abel, Tareq Al Baghdadi, H. Joachim Deeg, James M. Foran, Steven D. Gore, Alexandra M. Harrington, Steven H. Kroft, Jane Jijun Liu, Wael Saber, Shamsuddin Virani, Rafael Bejar, R. Coleman Lindsley, Eric Padron, Matthew J. Walter, Rami Komrokji, Amy E. DeZern, Mikkael A. Sekeres   +25 more
wiley   +1 more source